Drugs / Mevac-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06298708 | Apr → Dec 2024 | hepatitis A virus infection | Chiang Mai University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mevac-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06298708 ↗ |
| Modality | Vaccine | “live-attenuated hepatitis A vaccine” NCT06298708 ↗ |
| Route | Subcutaneous | “subcutaneous injection of 0.5 ml” NCT06298708 ↗ |